Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 4, 2004 - Issue 6
Submit an article Journal homepage
19,453
Views
24
CrossRef citations to date
0
Altmetric
Editorial

Four quadrants of the cost-effectiveness plane: some considerations on the south-west quadrant

Rogier M Klok Groningen University Institute for Drug Exploration, Department of Social Pharmacy, Pharmacoepidemiology and Pharmacotherapy, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands. [email protected]
&
Maarten J Postma Groningen University Institute for Drug Exploration, Department of Social Pharmacy, Pharmacoepidemiology and Pharmacotherapy, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands. [email protected]
Pages 599-601 | Published online: 09 Jan 2014

References

  • Diener A, O'Brien B, Gafni A. Healthcare contingent valuation studies: a review and classification of the literature. Health Econ. 7(4), 313–326 (1998).
  • Klok RM, Arents NL, de Vries R et al. The economic evaluation of a randomized trial comparing 'test-and-treat' with prompt endoscopy in primary care; the health economics of the SENSE-study. Value Health 7 (6), 754 (2004).
  • O'Brien BJ, Gertsen K, Witten AR, Faulkner LA. Is there a kink in consumers' threshold value for cost-effectiveness in healthcare? Health Econ. 11,175–180 (2002).
  • van Flout BA, Al MJ, Gordon GS, Rutten FE Costs, effects and C/E-ratios alongside a clinical trial. Health Econ. 3(5), 309–319 (1994).
  • Fenwick E, O'Brien BJ, Briggs A. Cost- effectiveness acceptability curves-facts,fallacies and frequently asked questions. Health Econ. 13(5), 405–415 (2004).
  • Hanemann WM. Willingness to pay and willingness to accept: how much can they differ? Am. Econ. Rev 18(3), 635–647 (1991).
  • Kahneman D, Tversky A. Prospect theory: an analysis of decision under risk. Econometrica 47(2), 263–291 (1979).
  • Dowie J. Why cost-effectiveness should trump (clinical) effectiveness: the ethical economics of the South West quadrant. Health Econ. 13,453–459 (2004).
  • Lazaro A. Theoretical arguments for the discounting of health consequences; where do we go from here? PharmacoEconomics 14,943–961 (2002).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.